Home / Catalogue/ Longevity/ SS-31 (Elamipretide)

LongevityIn StockSubQ injection

SS-31 (Elamipretide)

Tetrapeptide · Mitochondria-targeting · 4 amino acids

Half-life

~3-6h

After administration

Delivery Method

SubQ injection

Route of administration

Storage (Lyophilised)

12-24 months

2–8°C

Storage (Reconstituted)

4–6 weeks

Refrigerate at 2-8C

Known For

Mitochondria-targeted peptide. Penetrates and concentrates in the inner mitochondrial membrane. Reduces oxidative stress, improves mitochondrial efficiency, and protects against age-related mitochondrial decline. Being studied for heart failure and mitochondrial diseases.

Mechanism of Action

Mitochondria-targeted peptide — penetrates inner mitochondrial membrane, stabilizes cardiolipin, improves electron transport chain efficiency. "Mitochondrial medicine."

Body vs. External Supply

🔴 Exogenous (replaces natural)

Brand / Trade Names

Elamipretide (INN name) Developer: Stealth BioTherapeutics Not yet approved Phase 3 trials ongoing

Typical Research Dosage

0.5-5mg/day SubQ. Clinical trials used 4mg/day and 40mg IV.

Vial Duration Guide

10mg vial at 2mg/day = 5 days. 50mg at 2mg/day = 25 days.

Recommended Vial Size

★ 10mg for trials, 50mg for protocols At 2mg/day, 10mg = 5 days ✓. 50mg = 25 days ✓. Both within shelf life. 50mg better value for committed protocols.

Time to Effects

EARLY: 1-2 weeks FULL: 8-12 weeks Week 1-2: Subtle energy improvements as mitochondrial function enhances. Week 2-4: Improved exercise tolerance. Better recovery. Reduced fatigue. Week 4-8: Noticeable improvements in cardiovascular endurance and cellular energy. Week 8-12: Full mitochondrial optimisation. Effects are subtle and cumulative. Most noticeable in individuals with compromised mitochondrial function or age-related decline. Minimum commitment: 8 weeks.

Contraindications & Do Not Combine

No strict contraindications with other peptides on this list.

Common Side Effects

Injection site reactions (most common), headache, dizziness. TANGO trial: generally well tolerated.

Drug Interactions

Unknown — limited drug interaction data. Theoretically could interact with mitochondrial toxins (aminoglycosides, NRTIs).

Reversibility

Reversible — mitochondrial function returns to pre-treatment levels

Key Peer-Reviewed References

All studies are published in indexed journals unless otherwise noted.

• Szeto (2014) Br J Pharmacol 171:2029-50 — Mitochondrial targeting • TANGO Phase 3: Barth Syndrome (NCT03098797) • Stealth BioTherapeutics development • NOT YET FDA APPROVED — Failed primary endpoint in Barth Syndrome trial but further trials ongoing • Promising mechanism but clinical translation challenging

Research Disclaimer

Almost all data is preclinical (animal or in-vitro). No large-scale randomised controlled human trials are available for most compounds on this catalogue. This information is provided for research reference only.

Storage Requirements

2-8°C (clinical supply)

State	Condition	Duration
Lyophilised (sealed)	2–8°C	12-24 months
Reconstituted	2-8C	4–6 weeks

Reconstitution Note

Reconstitute with bacteriostatic water (BAC water). Do not shake vigorously -- swirl gently to dissolve. Inject BAC water slowly down the side of the vial to avoid denaturing the peptide.

Video Resources

SS-31 (Elamipretide) discussed by researchers & practitioners

Independent educational content from researchers, clinicians, and science communicators. Not affiliated with Pepnerd — provided as supplementary reading.

Educational resources only. The videos above are independent third-party content from researchers, clinicians, and science communicators. Pepnerd is not affiliated with any of these creators and does not endorse or make any claims based on their content. All products are sold strictly for in-vitro scientific research.

Select Vial Size

$105.00 per vial

Submit Your Test Results →

Quick Reference

Half-life	~3-6 hours (estimated)
Delivery	SubQ injection
Typical dose	0.5-5mg/day
Storage (lyoph.)	2–8°C
Storage (recon.)	4–6 weeks
Endogenous?	Exogenous (replaces natural)
Suppression	None known
WADA	Not listed — investigational
FDA status	Phase 2/3 trials